slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 2,671-2,700
Pages 619
Rows per page 30
Component
2,671-2,700 of 18,554
116
Contains highlighted text segments within the quotes.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
132
The slide uses a 'villain' narrative framing, comparing the medical system to a cartel and highlighting the 'addiction to volume' as a driver for TransMedics service adoption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
151
The slide presents two Q&A excerpts from a transplant surgeon to support the claim that TransMedics is hijacking the organ allocation process.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
158
The slide uses a testimonial/interview format to challenge the necessity of the OCS device for local transplants.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
160
The slide uses direct quotes from transplant directors to challenge the value proposition of TransMedics' NOP service.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
167
Uses direct quotes from surgeons at Utah and UCSD to support the thesis of off-label, convenience-driven usage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
168
The slide uses direct quotes to highlight a discrepancy between the purported clinical value of the device and the actual operational use case.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
169
The slide uses direct quotes from anonymous experts to build a case of 'expensive abuse' of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
171
The slide uses expert quotes to frame 'back to base' usage as a potentially harmful, off-label practice driven by convenience rather than clinical necessity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
172
The slide uses a Q&A format to highlight a specific industry pain point regarding the misuse of medical technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
175
The slide uses a 'villain_critique' approach by quoting an ex-employee to expose what the author considers to be fraudulent medical claims.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
186
The slide uses expert testimony to challenge the value proposition of the TransMedics technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
196
The slide uses direct quotes from a transplant surgeon to validate the claim of incompetence and poor operational performance.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
202
The slide uses direct quotes to highlight negative perceptions of TransMedics' hiring practices and surgeon qualifications.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
204
The slide uses direct quotes to frame the subject as a villain/incompetent actor. It is a classic 'expert testimony' attack.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
207
The slide uses direct quotes to frame TransMedics' surgical practices as a liability and a regression in quality standards.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
210
The slide uses direct quotes from a former employee to build a case against the company's operational integrity.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
233
The slide uses testimonials from an OrganOx employee and a transplant cardiologist to argue that TransMedics' model strips control from hospitals and relies on inadequate communication methods like cell phone videos.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
239
The slide uses direct quotes to build a narrative of negligence and poor surgical technique.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
243
The slide uses direct quotes to highlight operational failures and lack of training in the field.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
245
The slide uses a Q&A format to highlight alleged safety violations and hospital staff complaints.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
247
The slide uses direct quotes to highlight operational risks and potential regulatory/ethical violations regarding the use of OCS specialists.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
252
The slide uses direct quotes from KOLs to build a negative narrative around the company's business ethics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
263
The slide uses a Q&A format to highlight a specific allegation of corporate dishonesty.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
270
The slide uses anecdotal evidence from a 'prominent surgeon' to support a bearish thesis on TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
277
The slide uses direct quotes from a high-volume TransMedics user to illustrate market vulnerability and the shift toward competitors offering more autonomy.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
283
The slide uses direct quotes from KOLs to frame the company's technology as a commoditized, overpriced solution with no clinical advantage over traditional cold storage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
289
The slide uses expert quotes to undermine the competitive moat of TransMedics by comparing it to existing, commoditized kidney perfusion technology.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
291
The slide uses direct quotes from a surgeon to undermine the company's value proposition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits
294
The slide uses direct quotes from surgeons to validate the market share shift thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 3 hits